Pain Relief: Unique Derivatives of Ibogaine Alleviate Both Acute and Chronic Pain Symptoms

Summary

Iboga derivatives, particularly iboga-alcohol, show significant potential as analgesics for both acute and chronic pain without the psychedelic effects associated with other Iboga compounds. The study found that these derivatives reduced paw diameter in response to formalin-induced pain and improved locomotor activity. Additionally, they mitigated inflammatory markers and reversed neurotrophic factor alterations linked to pain. Overall, these findings suggest promising applications for pain management in clinical settings.

Study at a glance

Abstract

Pain induction results in the initiation of neuroinflammatory and neurodegenerative processes, leading to neuromodulation, while conventional analgesic treatments frequently entail undesirable side effects. This research delves into the potent and selective analgesic attributes of Iboga derivatives in the context of acute and chronic pain models. Specifically, the study explores the effcacy of Iboga-alcohol (C1) against acute pain induced by formalin, and investigates the properties of novel derivatives, including iboga-amide (C2), iboga-methylamide (C3), and iboga ester-exo (C4) in terms of their antinociceptive, anti-inflammatory, and neuromodulatory effects. To assess pain, various methods were employed, such as measuring paw diameter, observing paw licking, conducting tail flick tests, hot plate tests, and Von Frey assessments. Additionally, the study evaluated locomotor activity and anxiety-like behavior through open field and elevated plus maze tests, while motor coordination was assessed via the rotarod test. Inflammatory mediators, neurotransmitters, and neurotrophic factors were quantified in serum, paw tissue, and spinal segments. All animal experiments were conducted following approval from Institutional Animal Ethics Committee, University of Calcutta approved by CCSEA, Government of India. The Iboga derivatives demonstrated a significant reduction in the increase in paw diameter induced by formalin. In acute pain models, ibogaine derivatives (C1, C3) reversed the reduced tail flick latency, and the restricted locomotor activity was notably improved by C1, C2, and C3. Anxiolytic behavior was observed in the groups treated with C1 and C3. The Iboga derivatives also mitigated inflammatory markers (Substance P, CGRP, COX-2, p65 nuclear translocation) and reduced serum IL-6 and TNF-α levels (C1). Iboga-alcohol effectively inhibited mechanical allodynia and heat hyperalgesia in chronic pain, along with ameliorating impaired motor activity. Iboga-analogues reversed BDNF depletion in acute pain and exaggerated GDNF elevation in response to noxious stimuli. These findings suggest that the novel Iboga derivatives, especially iboga-alcohol, demonstrate effective antinociceptive actions, prevent neuroinflammation, and hold promise as evidence-based candidates for drug development, without any psychedelic issues potentially offering unique solutions for clinical applications, including pain management in healthcare and sports performance enhancement. 1. West Bengal Department of Science and Technology Biotechnology, Government of West Bengal 2. Life Science Research Board, DRDO, Government of India. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Tags